Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00398853 · ClinicalTrials.gov registry record · Phase 4

Effect of Chromium Picolinate on Insulin Sensitivity in Type 2 Diabetes

A Phase 4 study, sponsored by Pennington Biomedical Research Center.

Completed
Registry status
Phase 4
Development phase
100
Enrollment target

NCT00398853: Completed Phase 4 study, sponsored by Pennington Biomedical Research Center.

NCT00398853 is a Phase 4 study that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 100 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00398853, a Phase 4 study, has completed, sponsored by Pennington Biomedical Research Center.

COMPLETED
Registry status
Phase 4
Development phase
100 participants
Enrollment target

Study Summary

The effect of Chromium to improve glucose levels in diabetes is controversial. The hypothesis of the study was to evaluate the effect of supplementing the diet of individuals with Type 2 diabetes with chromium picolinate and assessing the effect of the supplementation on insulin sensitivity as assessed with hyperinsulinemic clamps

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT chromium picolinate 1000 mcg daily vs placebo

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2003-10
Est. Completion 2009-06
Phase Phase 4

What the finished NCT00398853 record still lists

NCT00398853 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00398853 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00398853 about?

NCT00398853 is a clinical study titled "Effect of Chromium Picolinate on Insulin Sensitivity in Type 2 Diabetes". The effect of Chromium to improve glucose levels in diabetes is controversial. The hypothesis of the study was to evaluate the effect of supplementing the diet of individuals with Type 2 diabetes with chromium picolinate and assessing the effect of the supplementation on insulin sensitivity as asses...

What is the current status of trial NCT00398853?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2003-10. Estimated completion is 2009-06.

What interventions are being tested in trial NCT00398853?

The interventions under investigation include: Placebo (OTHER), chromium picolinate 1000 mcg daily vs placebo (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00398853?

This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00398853's enrollment target sits among peer trials

100 770th of 2000 higher than 1,148 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00398853, the US trial registry maintained by the National Library of Medicine. NCT00398853 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.